CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $458.09M |
| Gross Profit (TTM) | $323.33M |
| EBITDA | $12.43M |
| Operating Margin | 0.20% |
| Return on Equity | 29.50% |
| Return on Assets | -0.25% |
| Revenue/Share (TTM) | $8.89 |
| Book Value | $8.27 |
| Price-to-Book | 6.60 |
| Price-to-Sales (TTM) | 6.93 |
| EV/Revenue | 5.36 |
| EV/EBITDA | 157.82 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 52.20% |
| Shares Outstanding | $51.73M |
| Float | $49.45M |
| % Insiders | 3.13% |
| % Institutions | 103.35% |
Volatility is currently expanding
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.
Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.
CareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.
CareDx, BrightSpring and PACS Group are positioned for growth as digital health expands and workforce shortages reshape medical services.
Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants. On August 5, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 97,090 shares of common stock. With respect to 34 of the new employees, an aggregate of 93,090 of the RSUs will vest o.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue of $132 million, an increase of 52% year-over-year Testing Services revenue of $100 million, an increase of 61% year-over-year, and Testing Services volume of approximately 58,000, an increase of 17% year-o.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CDNA and any ticker you trade — then tracks every position and per-strategy win rate.
